RESELIP 10 mg/40 mg, tablet 30 tablets
Active ingredients: Atorvastatin, Atorvastatin calcium trihydrate, Ezetimibe
Commercialized according to BDPMDispensing in France: Prescription only
Tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- RESELIP 10 mg/40 mg, comprimé
- Pharmaceutical form
- comprimé
- Route of administration
- orale
- Presentation description
- plaquette(s) OPA : polyamide orienté aluminium PVC de 30 comprimé(s)
- Marketing authorisation holder
- BOUCHARA-RECORDATI
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 28 Apr 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64680744CIP73021278CIP133400930212783Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ATORVASTATINEcomprimé | 40 mg · un comprimé | FT |
| ÉZÉTIMIBEcomprimé | 10 mg · un comprimé | SA |
| ATORVASTATINE CALCIQUE TRIHYDRATÉEcomprimé | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.